title: A new target ligand Ser-Glu for PEPT1-overexpressing cancer imaging.
abstract: Nanoparticles functionalized with active target ligands have been widely used for tumor-specific diagnosis and therapy. The target ligands include antibodies, peptides, proteins, small molecules, and nucleic acid aptamers. Here, we utilize dipeptide Ser-Glu (DIP) as a new ligand to functionalize polymer-based fluorescent nanoparticles (NPs) for pancreatic cancer target imaging. We demonstrate that in the first step, Ser-Glu-conjugated NPs (NPs-DIP) efficiently bind to AsPC-1 and in the following NPs-DIP are internalized into AsPC-1 in vitro. The peptide transporter 1 inhibition experiment reveals that the targeting effects mainly depend on the specific binding of DIP to peptide transporter 1, which is remarkably upregulated in pancreatic cancer cells compared with varied normal cells. Furthermore, NPs-DIP specifically accumulate in the site of pancreatic tumor xenograft and are further internalized into the tumor cells in vivo after intravenous administration, indicating that DIP successfully enhanced nanoparticles internalization efficacy into tumor cells in vivo. This work establishes Ser-Glu to be a new tumor-targeting ligand and provides a promising tool for future tumor diagnostic or therapeutic applications.
authors.affiliation: State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, People's Republic of China.
authors.forename: Tongcheng
authors.initials: T
authors.lastname: Dai
authors.affiliation: State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, People's Republic of China.
authors.forename: Na
authors.initials: N
authors.lastname: Li
authors.affiliation: State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, People's Republic of China.
authors.forename: Lingzhi
authors.initials: L
authors.lastname: Zhang
authors.affiliation: State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, People's Republic of China; Shanghai Collaborative Innovation Center for Biomanufacturing Technology, Shanghai, People's Republic of China.
authors.forename: Yuanxing
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, People's Republic of China; Shanghai Collaborative Innovation Center for Biomanufacturing Technology, Shanghai, People's Republic of China.
authors.forename: Qin
authors.initials: Q
authors.lastname: Liu
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D049109:Cell Proliferation / Q000187:drug effects; D004151:Dipeptides / Q000737:chemistry / Q000494:pharmacology*; D005260:Female; D005434:Flow Cytometry; D005453:Fluorescence; D018698:Glutamic Acid / Q000737:chemistry*; D006801:Humans; D007091:Image Processing, Computer-Assisted; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry*; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D000074011:Peptide Transporter 1; D011108:Polymers / Q000737:chemistry*; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012694:Serine / Q000737:chemistry*; D027981:Symporters / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
chemical_list: D004151:Dipeptides; D000074011:Peptide Transporter 1; D011108:Polymers; D012333:RNA, Messenger; C082186:SLC15A1 protein, human; D027981:Symporters; D018698:Glutamic Acid; D012694:Serine
keywords: PEPT1 transporter; Ser–Glu; imaging; pancreatic cancer; target ligand
references.citation: Angiogenesis. 2013 Jul;16(3):503-24
references.pmid: 23543223
references.citation: J Nucl Med. 2008 Apr;49(4):615-22
references.pmid: 18344442
references.citation: Biomaterials. 2015 Feb;42:161-71
references.pmid: 25542804
references.citation: Annu Rev Med. 2012;63:185-98
references.pmid: 21888516
references.citation: Cancer Sci. 2013 Jul;104(7):779-89
references.pmid: 23495730
references.citation: Future Oncol. 2013 Mar;9(3):369-76
references.pmid: 23469972
references.citation: Mater Sci Eng R Rep. 2013 Mar;74(3):35-69
references.pmid: 24068857
references.citation: Int J Pancreatol. 1997 Dec;22(3):221-5
references.pmid: 9444554
references.citation: Int J Pharm. 2010 Jan 29;385(1-2):150-6
references.pmid: 19825404
references.citation: ACS Nano. 2011 Jun 28;5(6):4422-33
references.pmid: 21557611
references.citation: Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1235-40
references.pmid: 20080552
references.citation: Nat Protoc. 2008;3(6):1101-8
references.pmid: 18546601
references.citation: J Pharm Sci. 2003 Apr;92(4):691-714
references.pmid: 12661057
references.citation: Int J Nanomedicine. 2012;7:3803-11
references.pmid: 22888235
references.citation: ACS Comb Sci. 2012 Feb 13;14(2):108-14
references.pmid: 22263689
references.citation: Mol Cancer Ther. 2005 Apr;4(4):659-67
references.pmid: 15827340
references.citation: Int J Nanomedicine. 2015;10:1155-72
references.pmid: 25709439
references.citation: Int J Nanomedicine. 2015;10:1223-33
references.pmid: 25709444
references.citation: Int J Nanomedicine. 2015;10:1001-18
references.pmid: 25678788
references.citation: Cancer Res. 2006 Jul 1;66(13):6732-40
references.pmid: 16818648
references.citation: Nat Rev Cancer. 2005 Mar;5(3):161-71
references.pmid: 15738981
references.citation: Nat Commun. 2012;3:1193
references.pmid: 23149738
references.citation: Drug Metab Dispos. 2012 Aug;40(8):1556-65
references.pmid: 22584254
references.citation: Eur J Pharm Sci. 2010 Jun 14;40(3):202-8
references.pmid: 20307658
references.citation: Trends Biotechnol. 2014 Jan;32(1):32-45
references.pmid: 24210498
references.citation: Cancer Res. 1998 Feb 1;58(3):519-25
references.pmid: 9458100
references.citation: Chem Soc Rev. 2012 Apr 7;41(7):2971-3010
references.pmid: 22388185
references.citation: Nat Commun. 2014;5:3702
references.pmid: 24805848
references.citation: Adv Drug Deliv Rev. 2014 Feb;66:2-25
references.pmid: 24270007
references.citation: Mol Pharm. 2012 Aug 6;9(8):2168-79
references.pmid: 22734589